Endure Biotherapeutics

Endure Biotherapeutics, founded in 2020 and based in Cambridge, USA, is developing a proprietary platform using engineered native bacteria as durable live biotherapeutic products (LBTs). The core innovation involves isolating native bacteria from a host, genetically modifying them to produce therapeutic proteins, and re-administering them to engraft permanently in the gut, offering potential cures for metabolic and inflammatory diseases. The company is in the preclinical stage, led by a seasoned executive team, and its foundational technology has been validated in a peer-reviewed publication in *Cell*. EndureBio's strategy targets significant unmet needs in diseases like Phenylketonuria (PKU) and inflammatory bowel disease (IBD) by aiming for a one-time, curative treatment paradigm.

Engineered Native Bacteria platform: isolates native bacterial strains from a host, genetically engineers them to produce therapeutic proteins, and re-administers them as oral capsules designed to permanently engraft and colonize the gastrointestinal tract for long-term treatment.

EndureBio competes in the live biotherapeutic product (LBP) space against companies like Synlogic (synthetic biotic medicines) and Vedanta Biosciences (defined bacterial consortia). Its key differentiation is the use of 'native' bacteria as chassis for durable engraftment, a approach less common than using lab-adapted strains or complex microbial communities.